Hansa Biopharma announces key executive appointments to support continued growth
Hansa Biopharma (Nasdaq Stockholm: HNSA) has announced three key executive appointments to strengthen its leadership team ahead of potential US market expansion. Brian Gorman joins as Chief Legal Officer and Corporate Secretary, bringing over 20 years of global experience, including significant M&A expertise from roles at Sinclair Pharma, Calliditas Therapeutics, and Opiant Pharmaceuticals.
Sandra Frithiof has been appointed as Chief Human Resources Officer, leveraging 25 years of HR experience, notably in supporting US market entry at Calliditas Therapeutics. Additionally, Kerstin Falck Lagercrantz will join as VP Corporate Affairs, bringing extensive experience from Pfizer AB in corporate affairs and commercial operations.
These appointments come at a crucial time as Hansa prepares for two Phase 3 readouts and its first BLA submission while strengthening its US pre-commercial activities.
Hansa Biopharma (Nasdaq Stockholm: HNSA) ha annunciato tre nomine chiave nel suo team dirigenziale per rafforzare la leadership in vista di una possibile espansione nel mercato statunitense. Brian Gorman entra come Chief Legal Officer e Corporate Secretary, portando oltre 20 anni di esperienza globale, inclusa una significativa competenza in fusioni e acquisizioni maturata in Sinclair Pharma, Calliditas Therapeutics e Opiant Pharmaceuticals.
Sandra Frithiof è stata nominata Chief Human Resources Officer, con 25 anni di esperienza nelle risorse umane, in particolare nel supportare l’ingresso nel mercato USA presso Calliditas Therapeutics. Inoltre, Kerstin Falck Lagercrantz si unirà come VP Corporate Affairs, apportando una vasta esperienza da Pfizer AB in affari societari e operazioni commerciali.
Queste nomine arrivano in un momento cruciale mentre Hansa si prepara per due risultati di Fase 3 e la sua prima presentazione di BLA, rafforzando al contempo le attività pre-commerciali negli Stati Uniti.
Hansa Biopharma (Nasdaq Estocolmo: HNSA) ha anunciado tres nombramientos clave en su equipo ejecutivo para fortalecer su liderazgo ante una posible expansión en el mercado estadounidense. Brian Gorman se incorpora como Chief Legal Officer y Secretario Corporativo, aportando más de 20 años de experiencia global, incluyendo una destacada experiencia en fusiones y adquisiciones en Sinclair Pharma, Calliditas Therapeutics y Opiant Pharmaceuticals.
Sandra Frithiof ha sido nombrada Chief Human Resources Officer, con 25 años de experiencia en recursos humanos, especialmente apoyando la entrada al mercado estadounidense en Calliditas Therapeutics. Además, Kerstin Falck Lagercrantz se unirá como VP de Asuntos Corporativos, aportando amplia experiencia de Pfizer AB en asuntos corporativos y operaciones comerciales.
Estos nombramientos llegan en un momento crucial mientras Hansa se prepara para dos resultados de Fase 3 y su primera presentación de BLA, fortaleciendo al mismo tiempo sus actividades precomerciales en EE. UU.
한사 바이오파마 (나스닥 스톡홀름: HNSA)는 미국 시장 확장 가능성을 앞두고 리더십 팀을 강화하기 위해 세 명의 주요 임원 임명을 발표했습니다. 브라이언 고먼은 최고법률책임자 및 기업 비서로 합류하며, Sinclair Pharma, Calliditas Therapeutics, Opiant Pharmaceuticals에서의 M&A 경험을 포함해 20년 이상의 글로벌 경력을 보유하고 있습니다.
산드라 프리티오프는 최고인사책임자로 임명되었으며, Calliditas Therapeutics에서 미국 시장 진출 지원 경험을 포함해 25년의 인사 경력을 활용합니다. 또한 커스틴 팔크 라거크란츠가 기업담당 부사장(VP Corporate Affairs)으로 합류하며, Pfizer AB에서의 기업 업무 및 상업 운영 경험을 풍부하게 갖추고 있습니다.
이 임명들은 한사가 두 건의 3상 결과 발표와 첫 BLA 제출을 준비하고 미국 내 사전 상업 활동을 강화하는 중요한 시기에 이루어졌습니다.
Hansa Biopharma (Nasdaq Stockholm : HNSA) a annoncé trois nominations clés au sein de son équipe de direction afin de renforcer son leadership en vue d'une éventuelle expansion sur le marché américain. Brian Gorman rejoint l'entreprise en tant que Chief Legal Officer et Corporate Secretary, apportant plus de 20 ans d'expérience internationale, notamment une expertise significative en fusions-acquisitions acquise chez Sinclair Pharma, Calliditas Therapeutics et Opiant Pharmaceuticals.
Sandra Frithiof a été nommée Chief Human Resources Officer, forte de 25 ans d'expérience en ressources humaines, notamment dans le soutien à l'entrée sur le marché américain chez Calliditas Therapeutics. Par ailleurs, Kerstin Falck Lagercrantz rejoint en tant que VP Corporate Affairs, apportant une vaste expérience acquise chez Pfizer AB dans les affaires corporatives et les opérations commerciales.
Ces nominations interviennent à un moment crucial alors que Hansa se prépare à deux résultats de phase 3 et à sa première soumission de BLA, tout en renforçant ses activités pré-commerciales aux États-Unis.
Hansa Biopharma (Nasdaq Stockholm: HNSA) hat drei wichtige Führungskräfte ernannt, um das Führungsteam im Vorfeld einer möglichen Expansion auf dem US-Markt zu stärken. Brian Gorman tritt als Chief Legal Officer und Corporate Secretary bei und bringt über 20 Jahre globale Erfahrung mit, darunter umfassende M&A-Kenntnisse aus Positionen bei Sinclair Pharma, Calliditas Therapeutics und Opiant Pharmaceuticals.
Sandra Frithiof wurde zur Chief Human Resources Officer ernannt und verfügt über 25 Jahre HR-Erfahrung, insbesondere bei der Unterstützung des Markteintritts in den USA bei Calliditas Therapeutics. Zudem wird Kerstin Falck Lagercrantz als VP Corporate Affairs hinzukommen und bringt umfangreiche Erfahrung von Pfizer AB in den Bereichen Unternehmensangelegenheiten und kommerzielle Operationen mit.
Diese Ernennungen erfolgen zu einem entscheidenden Zeitpunkt, da Hansa sich auf zwei Phase-3-Ergebnisse und die erste BLA-Einreichung vorbereitet und gleichzeitig seine US-amerikanischen Vorvermarktungsaktivitäten stärkt.
- Strategic strengthening of executive team with experienced leaders ahead of potential US market entry
- Addition of legal expertise with significant M&A background through new CLO appointment
- Enhancement of HR capabilities with focus on US market expansion
- Upcoming catalysts with two Phase 3 readouts and first BLA submission
- Multiple simultaneous leadership changes may create temporary organizational adjustment period
- Departure of existing executives including CHRO and VP Corporate Affairs indicates organizational restructuring
Brian Gorman is an accomplished legal and business executive with more than 20 years of global experience in advising corporate boards and management teams. Brian joins Hansa from Sinclair Pharma Ltd., a global medical aesthetics company, where he was Chief Legal Officer supporting the company's global expansion efforts. Prior to Sinclair, Brian was Group General Counsel at Calliditas Therapeutics, where he guided the company through its acquisition by Asahi Kasei Corporation of
Sandra Frithiof brings over 25 years of experience in human resources in different industries, to Hansa. Most recently, Sandra was HR Director at Ayvens Sweden AB, a global leader in the mobility sector. Prior to Ayvens, Sandra was VP Human Resources at Calliditas Therapeutics, where she built the Global HR organization to support the company's entry into the US market. Previously, Sandra was Head of HR and COO at Ramberg Advokater, a Swedish law firm and earlier in her career, Sandra held HR positions at Karolinska University Hospital, UTC, CGI and Manpower Group. Sandra has a bachelor's degree in human resource management from Örebro University,
Brian Gorman and Sandra Frithiof will report to CEO Renée Aguiar-Lucander and be members of the Executive Committee.
Kerstin Falck Lagercrantz will join Hansa from Pfizer AB, where she has spent over 20 years in various positions in corporate affairs and commercial operations. Between 2014-2022, Kerstin held the role of Corporate Affairs Director where she was responsible for external communications, patient affairs, corporate social responsibility and crisis and issues management. During this time, she successfully implemented agreements and influenced several health policies during the COVID-19 pandemic. In addition, Kerstin has held several positions with SwedenBIO, including member of the board, and multiple roles with LIF (Swedish Pharmaceutical Industry Association). She has a Degree of Bachelor of Science in Business Administration and Economics, from Uppsala University,
"We are very pleased to welcome Brian, Sandra and Kerstin to Hansa. They bring invaluable experience in their respective areas of expertise, which will be critical as we step up our US pre-commercial activities, subject to data from two Phase 3 readouts and our first BLA submission" said CEO Renée Aguiar-Lucander.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB,
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
20250729 - HNSA Executive Appointments |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-announces-key-executive-appointments-to-support-continued-growth-302516357.html
SOURCE Hansa Biopharma AB
FAQ
Who are the new executives joining Hansa Biopharma (HNSA) in 2025?
What is Brian Gorman's background before joining Hansa Biopharma?
Why is Hansa Biopharma (HNSA) making these executive appointments in 2025?
What experience does Sandra Frithiof bring to Hansa Biopharma as new CHRO?
What are Hansa Biopharma's (HNSA) upcoming major milestones in 2025?
